Sellas Life Sciences is trading 11.05% down now at $12.00 after no clear company-specific catalyst emerged on September 11, 2026.

  • The latest identified company announcement was September 2, when Sellas announced planned preclinical SLS009 pancreatic-cancer presentations at the AACR conference.
  • That announcement does not directly explain the current decline.
  • Broader markets are sharply higher, making a market-wide selloff an unlikely explanation.